Clinical Trials Browser

Terminated × itacitinib × Clear all

Carcinoma, Non-Small-Cell Lung

NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Phase 1 Terminated

27 enrolled

Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

NCT03272464 2023-09-22

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Phase 1 Terminated

1 enrolled 6 charts

Dermatologic

Melanoma

NCT03425006 2023-09-13

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

Phase 2 Terminated

23 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02265510 2020-04-17

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Phase 1/2 Terminated

83 enrolled 31 charts

Tumor-Agnostic

Neoplasm Metastasis

NCT02559492 2019-09-25

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

Phase 1 Terminated

142 enrolled

Other solid neoplasm

Solid Tumors

NCT02456675 2018-01-12

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Phase 2 Terminated

8 enrolled

Lymphoid

Hodgkin Disease

Clinical Trials

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma